About Eidos Therapeutics
Eidos Therapeutics is a Healthcare company based in Palo Alto (United States) founded in 2016 by Isabella Graef, Neil Kumar, and Mamoun Alhamadsheh, and was acquired by BridgeBio in October 2020. Small-molecule treatments for transthyretin amyloidosis are developed. Eidos Therapeutics has raised $64 million across 1 funding round from investors including BridgeBio, Janus Henderson Investors and RA Capital. Its chief executive, as recorded, is Neil Kumar. Eidos Therapeutics offers products and services including Attruby and Nulibry. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is BridgeBio Pharma, Inc. Its competitors include BridgeBio, Moderna and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Eidos Therapeutics was founded in 2016 in Palo Alto, United States, as a biotechnology firm focused on rare diseases. Small-molecule therapies are developed to address transthyretin (TTR) amyloidosis, with the lead candidate AG10 designed to stabilize TTR proteins and inhibit amyloid formation. Both hereditary and wild-type forms of the disease are targeted through these operations, which emphasize clinical advancement in the therapeutic sector.
- Headquarters Palo Alto, United States
- Founders Isabella Graef, Neil Kumar, Mamoun Alhamadsheh
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website eidostx.com
- Social LinkedIn X YouTube
- Acquired by BridgeBio (Oct 2020)
- Legal Name Bridgebio Pharma, Inc.
Products & Services of Eidos Therapeutics
Eidos Therapeutics offers a comprehensive portfolio of products and services, including Attruby and Nulibry.
Approved drug for treating specific genetic diseases effectively.
Medicine targeting genetic conditions to improve patient outcomes.
Apps and channels of Eidos Therapeutics
its YouTube channel BridgeBio Pharma has 283 subscribers and 30 videos.
Videos from Eidos Therapeutics
The most watched videos on Eidos Therapeutics's YouTube channel, BridgeBio Pharma (283 subscribers). Click a video to play it here.
More on BridgeBio Pharma.
Funding Insights of Eidos Therapeutics
Eidos Therapeutics has successfully raised a total of $64M through 1 strategic funding round. The most recent funding activity was a Series B round of $64 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $64M
- Total Rounds 1
- Last Round Series B — $64M
- First Round $64M
(Apr 2018)
- Investors Count 8
All 1 funding rounds of Eidos Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $64M | Series B | – | RA Capital Management, BridgeBio |
8 investors in total: 8 institutional.
Investors in Eidos Therapeutics
Eidos Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include BridgeBio, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Amzak Health is engaged in venture investments in life sciences. | amzakhealth.com | New York, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | bridgebio.com | Palo Alto, United States | |
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States |
Investor details for Eidos Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eidos Therapeutics
17 people are tracked at Eidos Therapeutics (13 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Isabella Graef | Co-Founder | Leadership |
Neil Kumar | Co-Founder & CEO | Leadership |
Mamoun Alhamadsheh | Co-Founder | Leadership |
Kristine Ha | Senior Director, Regulatory Operations | Leadership |
Uma Sinha | Chief Scientific Officer | Leadership |
Ananth Sridhar | Senior Vice President, Corporate Development | Leadership |
Stuart Heminway | Senior Vice President, Regulatory Affairs, BridgeBio Cardiorenal | Leadership |
Matt Outten | Chief Commercial Officer | Leadership |
Olga Vlaskina | Director of Administration and Operations | Leadership |
Leonid K. | Senior Vice President, Clinical Development | Leadership |
Suliat Oyelami-Davies | Director, Clinical Operations | Leadership |
Mark McGovern | Vice President Clinical Operations | Leadership |
Suresh Siddhanti | Vice President, Clinical Development | Leadership |
Jonathan Fox | MD, PhD, FACC | Team |
Alan Xian Ji | Scientist | Team |
Justin Collaço | Clinical Research Associate I | Team |
Tanya OShea | Relationship Site Manager/Clinical Operations Consultant | Team |
Complete people profiles for Eidos Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eidos Therapeutics
3 dated milestones of Eidos Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Eidos Therapeutics is founded.
- Funding First funding round of $64.0M.
- Exit Acquired by BridgeBio.
Competitors of Eidos Therapeutics
Eidos Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Moderna and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Eidos Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Eidos Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eidos Therapeutics
Complete news archive for Eidos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eidos Therapeutics
Eidos Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Eidos Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Neil Kumar is the CEO of Eidos Therapeutics, as recorded in our data. They have also founded this company.
Eidos Therapeutics is a funded company, having raised a total of $64M across 1 funding round to date. The company's 1st funding round was a Series B of $64M, raised on Apr 2018.
Eidos Therapeutics was founded in 2016 in Palo Alto, United States, as a biotechnology firm focused on rare diseases. Small-molecule therapies are developed to address transthyretin (TTR) amyloidosis, with the lead candidate AG10 designed to stabilize TTR proteins and inhibit amyloid formation. Both hereditary and wild-type forms of the disease are targeted through these operations, which emphasize clinical advancement in the therapeutic sector.
Eidos Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Eidos Therapeutics offers Attruby and Nulibry.
Eidos Therapeutics has 8 investors. Key investors include BridgeBio, Janus Henderson Investors, RA Capital, Perceptive Advisors, and Viking Global Investors.
Eidos Therapeutics operates through Bridgebio Pharma, Inc..
Yes. Eidos Therapeutics was acquired by BridgeBio in October 2020.